Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstrom macroglobulinemia (WM).

被引：0
|
作者：
Lasica, Masa
Ailawadhi, Sikander
Fu, Chengcheng
Thomas, Sheeba K.
Wu, Depei
Yi, Shuhua
Siddiqi, Tanya
Yin, Qingsong
Allan, John N.
Chen, Wenming
Matous, Jeffrey V.
Feng, Ru
Chen, Zi
Yu, Min
Li, Mingyu
He, Zicong
Ahmad, Mohammad
Wang, Hengbang
Chanan-Khan, Asher Alban Akmal
Zhai, Yifan
机构：
[1] St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[2] Mayo Clin Florida, Jacksonville, FL USA
[3] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
[6] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Weill Cornell Med, New York, NY USA
[9] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
[10] Colorado Blood Canc Inst, Denver, CO USA
[11] Sarah Cannon Res Inst, Denver, CO USA
[12] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[13] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[14] Ascentage Pharma Grp Inc, Rockville, MD USA
[15] Ascentage Pharma Pty Ltd, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7078
引用
收藏
页数：1
相关论文
共 28 条
  • [1] Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstrom macroglobulinemia (WM)
    Ailawadhi, Sikander
    Lasica, Masa
    Fu, Chengcheng
    Thomas, Sheeba K.
    Wu, Depei
    Yi, Shuhua
    Siddiqi, Tanya
    Yin, Qingsong
    Allan, John N.
    Chen, Wenming
    Matous, Jeffrey V.
    Feng, Ru
    Chen, Zi
    Yu, Min
    Li, Mingyu
    He, Zicong
    Ahmad, Mohammad
    Wang, Hengbang
    Chanan-Khan, Asher Alban Akmal
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
    Wang, Huafeng
    Wei, Xudong
    Liang, Yang
    Weng, Jianyu
    He, Wenjuan
    Chang, Chunkang
    Chen, Suning
    Ma, Hongbing
    Chen, Zi
    Men, Lichuang
    Liu, Lihui
    Tian, Xiaohong
    Zhang, Zhang
    Cong, Danhua
    Yang, Dajun
    Zhai, Yifan
    Jin, Jie
    BLOOD, 2024, 144 : 3202 - 3203
  • [3] Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
    Paulus, Aneel
    Manna, Alak
    Wang, Hengbang
    Chen, Jianyong
    Min, Ping
    Yin, Yan
    Dutta, Navnita
    Halder, Nabanita
    Ciccio, Gina
    Copland, John
    Han, Bing
    Bai, Longchuan
    Liu, Liu
    Wang, Mi
    McEachern, Donna
    Przybranowski, Sally
    Yang, Chao-Yie
    Stuckey, Jeanne
    Wu, Depei
    Li, Caixia
    Ryan, Jeremy
    Letai, Anthony
    Ailawadhi, Sikander
    Yang, Dajun
    Wang, Shaomeng
    Chanan-Khan, Asher
    Zhai, Yifan
    LEUKEMIA & LYMPHOMA, 2023, 64 : S79 - S79
  • [4] Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
    Deng, Jing
    Paulus, Aneel
    Fang, Douglas D.
    Manna, Alak
    Wang, Guangfeng
    Wang, Hengbang
    Zhu, Saijie
    Chen, Jianyong
    Min, Ping
    Yin, Yan
    Dutta, Navnita
    Halder, Nabanita
    Ciccio, Gina
    Copland III, John A.
    Miller, James
    Han, Bing
    Bai, Longchuan
    Liu, Liu
    Wang, Mi
    McEachern, Donna
    Przybranowski, Sally
    Yang, Chao-Yie
    Stuckey, Jeanne A.
    Wu, Depei
    Li, Caixia
    Ryan, Jeremy
    Letai, Anthony
    Ailawadhi, Sikander
    Yang, Dajun
    Wang, Shaomeng
    Chanan-Khan, Asher
    Zhai, Yifan
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5455 - 5468
  • [5] Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
    Zhou, Keshu
    Sun, Mingyuan
    Wei, Xu
    Yi, Shuhua
    Qi, Junyuan
    Nian, Weiqi
    Cui, Guohui
    Wang, Jishi
    Zhang, Xiaoping
    Cen, Hong
    Zhou, Fuling
    Huang, Jianying
    Liu, Huilan
    Shen, Aizong
    Geng, Liangquan
    Feng, Ru
    Xu, Chongyuan
    Qian, Wenbin
    Li, Fei
    Liu, Lihong
    Li, Caixia
    Zhao, Xielan
    Jin, Jie
    Jing, Hongmei
    Ji, Dongmei
    Lyu, Fangfang
    Chen, Zi
    Men, Lichuang
    Wang, Hengbang
    Zhang, Ke
    Xu, Liang
    Zhang, Zhang
    Yang, Dajun
    Wang, Jianxiang
    Li, Jianyong
    Zhai, Yifan
    BLOOD, 2023, 142
  • [6] First-in-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients With Relapsed/Refractory CLL and Other Hematologic Malignancies
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 10 - 11
  • [7] Combination of olverembatinib (HQP1351) with BCL-2 inhibitor lisaftoclax (APG-2575) overcomes resistance in gastrointestinal stromal tumors (GISTs)
    Min, Ping
    Wang, Guangfeng
    Liang, Eric
    Wu, Bingxing
    Yu, Huidan
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2023, 83 (07)
  • [8] First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban Akmal
    Chen, Zi
    Huang, Bo
    Konopleva, Marina
    Brander, Danielle M.
    Rizzieri, David
    Lasica, Masa
    Tam, Constantine Si Lun
    Yannakou, Costas K.
    Prince, H. Miles
    Davids, Matthew Steven
    He, Zhicong
    Lu, Ming
    Ahmad, Mohammad
    Li, Mingyu
    Liang, Zhiyan
    Mudenda, Boyd
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)
    Sun, Mingyuan
    Qi, Junyuan
    Chen, Zi
    Zhang, Hongli
    Song, Yongping
    Shen, Aizong
    Liu, Huilan
    Huang, Jianying
    Zhou, Fuling
    Jin, Jie
    Lu, Ming
    Ahmad, Mohammad
    Men, Lichuang
    Cen, Wan
    Yang, Dajun
    Wang, Jianxiang
    Zhai, Yifan
    BLOOD, 2021, 138 : 3730 - +
  • [10] Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naive (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms
    Wang, Huafeng
    Wei, Xudong
    Jiang, Qian
    He, Wenjun
    Li, Qiubai
    Liang, Yang
    Weng, Jianyu
    Chen, Suning
    Ma, Hongbing
    Chang, Chukang
    Xu, Yajing
    He, Qun
    Chen, Zi
    Liu, Lihui
    Men, Lichuang
    Cong, Danhua
    Zhang, Zhang
    Yang, Dajun
    Zhai, Yifan
    Jie, Jin
    BLOOD, 2023, 142
123